At a meeting Monday, the Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 that donanemab is effective at slowing down Alzheimer’s in the disease’s early stages
this is how efficacy is determined? by committees voting?? seems weird
Presumably the committee members would be experts in their field that would weigh the evidence accordingly and come to a decision. They would vote because it's a better failsafe than having one guy just sign off on the whole thing.
No idea of that's how it works in practice, but it does make sense imo.
